Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Singlera Raises $60 Million in A+ Round for Cancer Tests

publication date: Mar 27, 2018

Singlera Genomics raised $60 million in an A+ round to expand its portfolio of non-invasive genetic diagnostics for cancer. The company, which operates in La Jolla, California and Shanghai, bases its tests on proprietary technologies that analyze cell-free DNA. Singlera offers five products for cancer screening, diagnosis and personalized treatment. The funding was co-led by Green Pine Capital Partners and Prosperico Ventures with participation from new and existing investors UCF Medical Investment, Jointown Pharmaceutical Group and Lilly Asia Ventures. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital